Clinical Trial Update: (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST [Phase 3]

View source ↗

Summary

Phase 3 trial comparing avapritinib to regorafenib in locally advanced unresectable or metastatic GIST has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Avapritinib (avapritinib)
• Regorafenib (regorafenib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: GIST | Phase 3 | Status: COMPLETED | Results posted: 2021-05-14